Portal de Periódicos da CAPES

Prostate Biopsy Tumor Extent but Not Location Predicts Recurrence After Radical Prostatectomy: Results From CaPSURE

2005; Lippincott Williams & Wilkins; Volume: 175; Issue: 1 Linguagem: Inglês

10.1016/s0022-5347(05)00056-x

1527-3792

Kirsten L. Greene, Eric P. Elkin, Armine Karapetian, Janeen DuChane, Peter R. Carroll, Christopher J. Kane,

Statistical Methods in Clinical Trials

No AccessJournal of UrologyAdult urology1 Jan 2006Prostate Biopsy Tumor Extent but Not Location Predicts Recurrence After Radical Prostatectomy: Results From CaPSUREis accompanied byThe Continuing Search for Meaningful Prognostic Information From Prostate Biopsy Kirsten L. Greene, Eric P. Elkin, Armine Karapetian, Janeen DuChane, Peter R. Carroll, Christopher J. Kane, and CaPSURE™ Investigators Kirsten L. GreeneKirsten L. Greene Department of Urology, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco More articles by this author , Eric P. ElkinEric P. Elkin Department of Urology, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco More articles by this author , Armine KarapetianArmine Karapetian Department of Urology, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco More articles by this author , Janeen DuChaneJaneen DuChane TAP Pharmaceutical Products, Inc., Lake Forest, Illinois Financial interest and/or other relationship with TAP Pharmaceuticals, Inc. More articles by this author , Peter R. CarrollPeter R. Carroll Department of Urology, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco Financial interest and/or other relationship with AstraZeneca, Steba Biotech N.V., Predicant Biosciences Inc., Watson Pharmaceuticals, National Cancer Institute, TAP Pharmaceuticals and ICPME. More articles by this author , Christopher J. KaneChristopher J. Kane San Francisco Veterans Affairs Medical Center, San Francisco, California Financial interest and/or other relationship with TAP Pharmaceuticals, Merck and AstraZeneca. More articles by this author , and CaPSURE™ Investigators More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)00056-XAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Prostate cancer biopsy information is important for patient risk assessment. Although the number and extent of positive biopsies have been used to predict recurrence, the impact of positive biopsy location and contiguity is less clear. We compared the ability of positive prostate biopsy location and pattern with number and percent positive biopsies to predict recurrence after RP. Materials and Methods: From CaPSURE we identified 2,037 men treated with RP from 1992 to 2002 for whom detailed biopsy information and 2 or more followup PSA values were available. Treatment failure was defined as 2 consecutive PSA values of 0.2 ng/ml or higher, or a second treatment delivered more than 6 months after RP. Biopsy tumor volume (number and percent positive sites), location of disease (anatomical site, laterality), and contiguity of positive biopsies were entered into Cox proportional hazards models to predict risk of disease recurrence while controlling for Gleason grade, PSA and T stage. Results: Higher number and percent of positive biopsy cores were associated with prostate cancer recurrence, risk stratification category and Gleason grade, p <0.0001, HR 1.09 (CI 1.02 to 1.16) and 1.01 (CI 1.00 to 1.01), respectively. Number of biopsy cores taken, laterality, contiguity and positive biopsy location were not associated with disease recurrence. Conclusions: The number and the percentage of biopsies positive for cancer correlated with treatment failure after radical prostatectomy. Contiguity, laterality and location were not associated with recurrence. References 1 : Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol2003; 170: S21. Link, Google Scholar 2 : Cancer statistics, 2004. CA Cancer J Clin2004; 54: 8. Google Scholar 3 : Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol2004; 171: 200. Link, Google Scholar 4 : Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol2001; 165: 851. Link, Google Scholar 5 : Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Mol Urol2000; 4: 171. Google Scholar 6 : Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol1999; 36: 21. Google Scholar 7 : Prostate cancer sampled on sextant needle biopsy: significance of cancer on multiple cores from different areas of the prostate. Urology1999; 54: 291. Google Scholar 8 : Correlation of positive prostate sextant biopsy locations to sites of positive surgical margins in radical prostatectomy specimens. Eur Urol2001; 39: 648. Google Scholar 9 : Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol2004; 172: 900. Link, Google Scholar 10 : The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer2003; 98: 2344. Google Scholar 11 : The CaPSURE database: a methodology for clinical practice and research in prostate cancer. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology1996; 48: 773. Google Scholar 12 : Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol2000; 163: 1171. Link, Google Scholar 13 : Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer1998; 82: 1887. Google Scholar 14 : Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol2004; 22: 3726. Google Scholar 15 : Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol2003; 169: 2136. Google Scholar 16 : Biopsy indication—a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease. Urology2004; 63: 887. Google Scholar 17 : Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology2003; 61: 589. Google Scholar 18 : Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol2004; 171: 1844. Link, Google Scholar 19 : Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol2003; 170: 1792. Link, Google Scholar 20 : Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol2003; 170: 459. Link, Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byPloussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou C and de la Taille A (2018) Pathological Findings and Prostate Specific Antigen Outcomes After Radical Prostatectomy in Men Eligible for Active Surveillance—Does the Risk of Misclassification Vary According to Biopsy Criteria?Journal of Urology, VOL. 183, NO. 2, (539-545), Online publication date: 1-Feb-2010.Eskicorapci S and Tuncay L (2018) Re: Diagnostic Value of Systematic Biopsy Methods in the Investigation of Prostate Cancer: A Systematic ReviewJournal of Urology, VOL. 176, NO. 6, (2745-2746), Online publication date: 1-Dec-2006.Related articlesJournal of Urology9 Nov 2018The Continuing Search for Meaningful Prognostic Information From Prostate Biopsy Volume 175Issue 1January 2006Page: 125-129 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsbiopsyrecurrenceprostatectomyprostatic neoplasmsMetricsAuthor Information Kirsten L. Greene Department of Urology, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco More articles by this author Eric P. Elkin Department of Urology, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco More articles by this author Armine Karapetian Department of Urology, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco More articles by this author Janeen DuChane TAP Pharmaceutical Products, Inc., Lake Forest, Illinois Financial interest and/or other relationship with TAP Pharmaceuticals, Inc. More articles by this author Peter R. Carroll Department of Urology, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco Financial interest and/or other relationship with AstraZeneca, Steba Biotech N.V., Predicant Biosciences Inc., Watson Pharmaceuticals, National Cancer Institute, TAP Pharmaceuticals and ICPME. More articles by this author Christopher J. Kane San Francisco Veterans Affairs Medical Center, San Francisco, California Financial interest and/or other relationship with TAP Pharmaceuticals, Merck and AstraZeneca. More articles by this author CaPSURE™ Investigators More articles by this author Expand All Advertisement PDF downloadLoading ...